Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20069544 | 0.86 | CTSK (0.33) | RETGRIN2BGRIN2CCTSK | |
| SCHEMBL20147374 | 0.83 | HRH3 (0.41) | HRH3 | |
| SCHEMBL20205793 | 0.82 | RET (0.50) | RETSIGMAR1 | |
| SCHEMBL12349920 | 0.79 | HRH3 (0.40) | GRIN2BGRIN2CHRH3SIGMAR1CTSK | |
| SCHEMBL20147320 | 0.77 | SETD7 (0.36) | RETHRH3 | |
| SCHEMBL21150506 | 0.76 | CTSK (0.39) | RETGRIN2BGRIN2CCTSKF2RL1 | |
| SCHEMBL20147386 | 0.75 | CHRM2 (0.40) | RETHRH3 | |
| SCHEMBL9937728 | 0.74 | CTSK (0.37) | GRIN2BGRIN2CCTSKF2RL1 | |
| SCHEMBL29092580 | 0.74 | CTSK (0.35) | RETGRIN2BGRIN2CCTSKF2RL1 | |
| SCHEMBL29092578 | 0.74 | CTSK (0.35) | RETGRIN2BGRIN2CCTSKF2RL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | RET 1/4885GRIN2B 1206/4885GRIN2C 1461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.